Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS)   Report issue

For profit Phase 2
Founded: Pittsburgh PA United States (2016)

Organization Overview

First Clinical Trial
2016
NCT02740972
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

viltolarsen (Viltepso) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1